<DOC>
	<DOCNO>NCT00119366</DOCNO>
	<brief_summary>This phase II trial study side effect best dose iodine I 131 monoclonal antibody BC8 give together fludarabine phosphate , total-body irradiation , donor stem cell transplant follow cyclosporine mycophenolate mofetil treat patient acute myeloid leukemia myelodysplastic syndrome spread place body usually cure controlled treatment . Giving chemotherapy drug , fludarabine phosphate , total-body irradiation donor peripheral blood stem cell transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . Also , radiolabeled monoclonal antibody , iodine I 131 monoclonal antibody BC8 , find cancer cell carry cancer-killing substance without harm normal cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving fludarabine phosphate total-body irradiation transplant together cyclosporine mycophenolate mofetil transplant may stop happen . Giving radiolabeled monoclonal antibody together donor stem cell transplant , cyclosporine , mycophenolate mofetil may effective treatment advance acute myeloid leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Iodine I 131 Monoclonal Antibody BC8 , Fludarabine Phosphate , Total Body Irradiation , Donor Stem Cell Transplant Followed Cyclosporine Mycophenolate Mofetil Treating Patients With Advanced Acute Myeloid Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate maximum tolerate dose ( MTD ) transplant-related mortality ( TRM ) toxicity deliver 131I-BC8 ( iodine I 131 monoclonal antibody BC8 ) ( anti-cluster differentiation [ CD ] 45 antibody ) start dose 22 Gy normal organ receive high dose combination non-myeloablative regimen fludarabine ( fludarabine phosphate ) ( FLU ) , 2 Gy total body irradiation ( TBI ) , cyclosporine ( CSP ) , mycophenolate mofetil ( MMF ) , human leukocyte antigen ( HLA ) -matched related unrelated allogeneic hematopoietic stem cell transplant ( HSCT ) patient 16 50 year old advance acute myeloid leukemia ( AML ) high risk myelodysplastic syndrome ( MDS ) . II . To estimate rate donor chimerism result combine preparative regimen correlate level donor chimerism estimate radiation dos deliver hematopoietic tissue via antibody . III . To determine rate disease relapse , graft vs. host disease , 2-year disease-free survival patient receive 131I-BC8 antibody combine FLU , 2 Gy TBI , CSP , MMF , HLA-matched relate unrelated allogeneic HSCT . OUTLINE : This dose-escalation study iodine I 131 monoclonal antibody BC8 . RADIOIMMUNOTHERAPY : Patients receive therapeutic iodine I 131 monoclonal antibody BC8 intravenously ( IV ) day -12 . CONDITIONING : Patients receive fludarabine phosphate IV day -4 -2 undergo TBI day 0 . TRANSPLANTATION : After completion TBI , patient undergo allogeneic peripheral blood stem cell ( PBSC ) transplant day 0 . IMMUNOSUPPRESSION : Patients match related donor receive cyclosporine IV orally ( PO ) twice daily ( BID ) day -3 56 follow taper day 180 absence graft-versus-host disease . Beginning 4-6 hour PBSC transplant , patient also receive mycophenolate mofetil PO BID day 0 27 . Patients match unrelated donor receive cyclosporine IV PO BID day -3 100 followed taper day 180 . Beginning 4-6 hour PBSC transplant , patient also receive mycophenolate mofetil PO thrice daily ( TID ) day 0 40 follow taper day 96 . After completion study treatment , patient follow 6 , 9 , 12 , 18 , 24 month annually thereafter .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Patients advance AML define beyond first remission , primary refractory disease , evolve myelodysplastic myeloproliferative syndrome ; patient MDS express refractory anemia excess blast ( RAEB ) , refractory anemia excess blast transformation ( RAEBT ) , refractory cytopenia multilineage dysplasia ( RCMD ) , RCMD ring sideroblast ( RCMDRS ) , chronic myelomonocytic leukemia ( CMML ) Patients remission must CD45expressing leukemic blast myelodysplastic cell ; patient remission require phenotyping may leukemia previously document CD45 negative ( remission patient , virtually antibody bind nonmalignant cell make &gt; = 95 % nucleated cell marrow ) Patients circulate blast count le 10,000/mm^3 ( control hydroxyurea similar agent allow ) Patients must estimate creatinine clearance great 50/ml per minute ( serum creatinine value must within 28 day prior registration ) Bilirubin &lt; 2 time upper limit normal Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2 time upper limit normal Karnofsky score &gt; = 70 Eastern Cooperative Oncology Group ( ECOG ) = &lt; 2 Patients must expect survival &gt; 60 day must free active infection Patients must HLAidentical sibling donor HLAmatched unrelated donor meet standard Seattle Cancer Care Alliance ( SCCA ) and/or National Marrow Donor Program ( NMDP ) donor center criterion peripheral blood stem cell ( PBSC ) donation ; relate donor match molecular method intermediate resolution level HLAA , B , C , developmentally regulate RNA bind protein 1 ( DRB1 ) accord Fred Hutchinson Cancer Research Center ( FHCRC ) Standard Practice Guidelines allele level DQB1 ; unrelated donor identify use match criterion follow FHCRC Standard Practice Guidelines limit study eligible donor allele match HLAA , B , C , DRB1 , DQB1 ( grade 1 ) , accept one allele mismatch per Standard Practice grade 2.1 HLAA , B , C DONOR : Donors must meet HLA match criterion well standard SCCA and/or NMDP donor center criterion PBSC donation Circulating antibody mouse immunoglobulin ( human antimouse antibody [ HAMA ] ) Prior radiation maximally tolerated level normal organ Patients may symptomatic coronary artery disease may cardiac medication antiarrhythmic inotropic effect Inability understand give inform consent Patients seropositive human immunodeficiency virus ( HIV ) Perceived inability tolerate diagnostic therapeutic procedure , particularly treatment radiation isolation Patients previously undergone autologous allogeneic HSCT</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>